Business
Spectral Diagnostics Announces Board Changes
TORONTO , July 26, 2013 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\nTORONTO, July 26, 2013 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the \"Corporation\") today announced that Mr. Ian Lennox and Mr. Ed McCormack have\n resigned as directors of the Corporation, effective August 1, 2013.\n\n\n\"Ian as Chairman of the Board of Directors, and Ed as Chairman of the\n Finance and Audit Committee, have made significant contributions to\n Spectral. They helped lead our transformation towards a therapeutic\n focus and lead the process of funding our mission, and achieving IFRS\n compliance. I am personally very grateful for their insights,\n leadership and guidance over their many years as board members,\" said\n Dr. Paul Walker, President and CEO of Spectral.\n\n\nAnthony Bihl, Chairman of the Board of Directors added, \"Ian and Ed\n brought exceptional experience, insight, and value to the Spectral\n Board, as they consistently focused on driving long term shareholder\n value.  Their contribution will be missed, and I thank them for all\n they have done for Spectral.\"\n\n\nThe Nomination & Governance Committee will commence a board governance\n review process to identify new directors for the board as well as the\n composition of the committees of the board.\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product (Toraymyxin) for the treatment of septic shock.\n Toraymyxin is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. Directed by\n the Company's Endotoxin Activity Assay (EAA™), the only FDA-cleared\n diagnostic for the risk of developing sepsis, Spectral's EUPHRATES\n trial is the world's first theranostics trial in the area of sepsis.\n\n\nSpectral is listed on the Toronto Stock Exchange under the symbol SDI,\n and on the OTC QX under the symbol DIAGF. For more information please\n visit www.spectraldx.com\n\nSOURCE: Spectral Diagnostics Inc.\n\n\n Spectral Diagnostics Inc.  Anthony Businskas Executive Vice President and CFO 416-626-3233 ext. 2200 Adam Peeler Investor Relations 416-815-0700 ext. [email protected] Copyright CNW Group 2013","length":3064,"tagName":"div"}]